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Abstract
Background Hematopoietic stem cell transplantation
(HSCT) is the only cure for patients with severe combined
immunodeficiency (SCID). The purpose of this study was
to evaluate long-term neurodevelopment of patients with
SCID following myeloablative chemotherapy and HSCT.
Materials and Methods Sixteen pediatric patients diag-
nosed with SCID were tested using the Bayley Scales of
Infant Development and the validated Vineland Adaptive
Behavior Scales (VABS) pre- and 1-year post-HSCT. Three
years post-HSCT, there were 11 patients available for
testing and four patients available 5 years post-HSCT.
Patients greater than 3 years of age were administered the
Wechsler Preschool and Primary Scale of Intelligence. Both
raw scores and scaled scores were analyzed.
Results There was a significant decrease 1 year post-HSCT
in the Bayley Mental Developmental Index (MDI) [92.5
(pre) vs. 70.81 (1 year post), p<0.0001] and the VABS
[99.73 (pre) vs. 79.87 (1 year post), p=<0.0001]. There was
a significant decrease over time in the MDI [95.00 (pre) vs.
72.64 (1 year post) vs. 71.82 (3 years post), p<0.0001], but
no significant change between 1 and 3 years post-HSCT.
There was no change in the Bayley Psychomotor Develop-
ment Scale (PDI) [82.4 (pre) vs. 84.8 (1 year post), p=
0.68]. The PDI scores decreased over time [86.29 (pre) vs.
86 (1 year post) vs. 74.14 (3 years post), p=0.045].
Although there was a decrease in scaled scores, there was
not a loss of skills. Analysis of raw scores showed that
there was an increase in the raw test scores, which indicated
that these children acquired developmental skills, but at a
slower rate than normal infants and toddlers. Younger
children had a more significant decrease in adaptive scores
compared with older children.
Conclusions These findings may reflect the effects of the
isolation and prolonged hospitalization that characterizes
the immediate post-transplant period. Patients miss out on
social interactions and learning opportunities that normally
occur at their respective stages of development. These
restrictions keep patients from acquiring developmentally
appropriate cognitive skills as well as gross and fine motor
developmental milestones. Longitudinal follow-up will be
important to quantify acquisition of skills.
Keywords SCID . Hematopoietic stem cell transplants .
long-term outcomes . development
Severe combined immunodeficiency (SCID) is a fatal
disorder that is characterized by defects in both cellular
and humoral immunity [1]. SCID occurs with an estimated
frequency of one in 75,000 births [2]. Patients present early
in life with a variety of opportunistic infections. Common
clinical manifestations include failure to thrive, candidiasis,
diarrhea, and pneumonia [3]. Hematopoietic stem cell
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transplantation (HSCT) offered the first cure for this disease
in 1968 [4]. Since then, HSCT is the treatment of choice for
patients with SCID.
Previous studies have yielded mixed results regarding
the neurodevelopmental function of patients following
HSCT. Some studies have shown no declines in neuro-
developmental function post-HSCT [5–8], whereas other
studies have shown declines post-HSCT [9–11]. Most of
these studies have included both malignant and non-
malignant diseases. Conditioning regimens consisted of
both irradiation and no irradiation. Consistently, however,
studies have shown that younger age was a factor in
decreased long-term neurodevelopmental deficits, especial-
ly among those who received radiation as part of their
therapy. Long-term evaluation of children less than 3 years
of age with leukemia who underwent HSCT showed
average intelligence but persistent attention deficits at a
median of 12 years post-HSCT [12].
The purpose of our study was to evaluate patients with a
single diagnosis (SCID) and analyze their long-term neuro-
development pre-, 1, 3, and 5 years post-HSCT. All patients
received a myeloablative conditioning regimen followed by
HSCT with either their haploidentical parent or an unrelated
donor.
Materials and Methods
All patients with SCID were eligible for this study. Long-
term follow-up protocols were approved by the Committee
on Clinical Investigations (Institutional Review Board of
Children’s Hospital Los Angeles). Consent was obtained
from all of the subjects’ parents or legal guardians. None of
the parents refused to participate in this study. Between
October 1997 and October 2006, we evaluated 24 patients
who had a diagnosis of SCID. Sixteen patients survived
beyond 1 year post-HSCT and were included in this study.
Individual patient characteristics are shown in Table I. A
schematic diagram of the patients available for testing at
different time points is shown in Fig. 1. All patients
received a myeloablative conditioning regimen using
Busulfan (16 mg/kg) and either Cytoxan or Campath 1H.
All patients were given total parenteral nutrition pre- and
post-HSCT until they were able to take adequate enteral
calories. All patients received occupational and physical
therapy twice a week. One neuropsychologist performed all
of the neurocognitive tests. Pre-HSCT evaluations were
performed within 1 month of HSCT. Follow-up exams were
performed at 1, 3, and 5 years post-HSCT. Due to
scheduling and transportation difficulties, examinations
were performed within 3 months of the scheduled date.
The Bayley Scales of Infant Development [13] was used for
patients between the ages of 1 and 42 months. The Bayley
provides scores of mental development (MDI) and psycho-
motor development (PDI). Patients >42 months of age
received the age-appropriate version of the Wechsler
Intelligence Scales (WPPSI) [14]. The WPPSI provides
scores of overall cognitive function as well as verbal and
performance skills. The unavoidable switch in test instru-
ments may or may not have caused bias in either increasing
or decreasing the patient’s test scores. Patients also received
the validated Vineland Adaptive Scales of Behavior
(VABS) [15], which provides scores of socialization and
adaptive behavior.
Statistics
Results are reported as mean±SD or median (min–max).
Within group, comparisons between test scores pre- and
1 year post-HSCT were made using paired t tests. Statistical
analysis of test scores pre- and 1 year and 3 years post-
HSCT was done using repeated measures analysis of
variance with post hoc, within-subject contrasts between
pre- vs. 1 year post-HSCT, and pre- vs. 3 years post-HSCT.
Pre-, 1 year, and 5 years post-HSCT scores were only
reported descriptively since there were not enough numbers
of patients for statistical analysis to be performed. Two-
sample t tests were used to compare change in scores
between subgroups of the patients who (1) were trans-
planted before and after 8 months of age, (2) had a history
of severe infections prior to transplantation, (3) received
more than one transplantation, and (4) length of stay in the
hospital. Spearman correlation coefficients were used to
examine associations between changes in the Bayley and
VABS scores. Analyses were performed using the Statisti-
cal Analysis System software (SAS, version 9). All
statistical tests were two-sided with α=0.05.
Results
Mental Developmental (MDI)
Sixteen patients received neurodevelopmental testing
pre- and 1 year post-HSCT. There was a significant
decrease in MDI in these patients from baseline to
1 year post-HSCT (92.6±12.7 vs. 70.8±21.2, p=0.0001;
Fig. 2). Eleven patients received neurodevelopmental
testing 3 years post-HSCT (Fig. 3). Nine patients received
the Bayley and two patients received the WPPSI. The
MDI of these patients showed a decrease from pre- to
1 year to 3 years post-HSCT (95.8±11.1 vs. 72.6±23.8 vs.
71.8±17.4, p=<0.0001). The greatest decrease in MDI
occurred between pre- and 1 year post-HSCT (p=0.0004).
The subsequent decline between 1 year post and 3 years
post-HSCT was not significant (p=0.8). Four patients
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Table I Individual Patient Characteristics
Patient Age at
transplant
(months)
Maternal
engraftment
Diagnosed
at birth
Infectious history
prior to HSCT
Type of transplant
chemoTx
More
than 1
transplant
Length of time
in hospital (months)
1 6.5 Yes/GVHD
at birth
No Minor infection Allo/haplo/BM No 2
Bu/Cy
2 9 No No PCP, RSV pneumonia Bu/Cy No 6
1 MUD
3 3.3 No Yes Minor infection Allo/haplo/BM No 8.3
Bu/Cy
4 11.8 Yes/GVHD
at birth
No Bacterial pneumonia,
intubated ARDS
2 Allo/haplo/BM Yes 4.7
Bu/Cy
5 14 Yes, GVHD
at birth
No Minor infection Allo/haplo/BM No 3.8
Bu/Cy
6 6.5 Yes/GVHD
at birth
No PCP, Mechanical
ventilation
Allo/haplo/PBSC No 4.8
Bu/Campath
7 2.5 No Yes Minor infection Allo/haplo/PBSC
Bu/Campath
Yes 8.5
1st-UCBT Bu/Cy
2nd-TBI/Flu/ΔTG
8 4.5 Yes/GVHD
at birth
No PCP, recurrent fungal
infection, candida
Allo/haplo/BM No 16.8 (discharge
delayed
awaiting
medical foster
care placement)
issues
Bu/Cy
9 2.5 Yes/GVHD
at birth
Yes Minor infection only Allo/haplo/BM No 6.9
Bu/Campath
10 6 No No Omenn’s syndrome,
chronic otitis
media/ mastoiditis
Allo/haplo/PBSC Yes 26.4
Bu/Cy
MUD BM
Bu/Flu/rATG
11 9 Yes/ GVHD
at birth
No Atypical pneumonia,
Candida
Allo/haplo No 3.8
Bu/Cy
12 2.5 No Yes Minor infection only Allo/haplo/PBSC Yes 7
Bu/Campath
Haplo/PBSC
Flu/rATG
Bu/Flu/rATG
13 10.5 Yes, but no
GVHD
at birth
No PCP-ventilator Allo/haplo/PBSC No 6
Bu/Campath
14 9.2 Yes/GVHD
at birth
No Pseudomonas
pneumonitis
Allo/haplo/PBSC No 11.7
Parainfluenza infxn-
ventilation ARDS
Bu/Campath
15 6 No No Seborrheic dermatitis,
(Omenn’s syndrome)
MUD/BM/Bu/
Cy/Flu/ATG
No 4.6
16 11.2 No No Chronic diarrhea,
failure to thrive.,
pseudomonas
pneumonia
Unrelated cord
blood, Bu/Cy/
Flu/ATG
No 13.6
BM bone marrow, Bu Busulfan, Cy Cytoxan, PBSC peripheral blood stem cell, TBI total body irradiation, Flu fludarabine, ATG antithymocyte
globulin, Allo allogeneic, Haplo haploidentical, MUD matched unrelated donor, UCBT unrelated cord blood donor, GVHD graft versus host
disease, PCP pneumocystis carinii pneumonia, RSV respiratory syncitial virus, ARDS acute respiratory distress syndrome
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were tested 5 years post-HSCT. One of these patients did
not return for their 3-year post-HSCT evaluation, but did
return for their 5-year post-HSCT evaluation. The MDI
was evaluated using the Bayley pre- and 1 year post-
HSCT and the WPPSI at 5 years post-HSCT. There was no
significant decrease in scores over time [89.5 (pre-HSCT)
and 87.5 (5 years post-HSCT), p=0.63]. We do not know
what the effect of changing test instruments is on this
population.
MDI scores were also analyzed to determine if there was
(1) an impact of younger age at transplantation, (2) an
impact of having severe infections prior to transplantation,
(3) having more than one transplant, and (4) length of stay.
The MDI scores pre- and 1 year post-HSCT for these
different variables are shown in Table II. With the small
numbers in the individual test groups, we could not detect
whether there was a difference between the different test
groups.
The raw scores for tests of MDI were also analyzed
(Fig. 4a). The median raw scores for MDI increased
slowly over time: Pre-HSCT MDI scores were 64 (24–
91) vs. 1 year post- HSCT scores 106 (89–151). Nine
patients received the Bayley at 3 years post-HSCT. The
median raw score for their MDI was 142 (114–158).
Since the test content and scoring vary for different
tests, the raw scores for those patients receiving the
WPPSI were not evaluated.
16 subjects
3 patients did not return/ moved away 
1 patient was too early to be tested 
1 patient died
1 year post-
HSCT  
11 subjects
3 year post-
HSCT  
4 subjects
5 year post-
HSCT  
Patients Demographics 
4 patients were too early to be tested 5 years
post- HSCT 
2 patients did not return/ moved away 
*1 patient moved back and was available for 
testing for 5 years post-HSCT 
Fig. 1 A schematic diagram of the patients available for testing at
different time points
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Fig. 2 Mental development scores, psychomotor development
scores, and adaptive behavior scores of SCID patients pre- and
1 year post-HSCT
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Fig. 3 Mental development scores and psychomotor development
scores of SCID patients pre-, 1 year, and 3 years HSCT
Table II Mental Development Scores of Patients Based on Age, Serious
Infection, Number of Transplants and Length of Stay (mean±SD)
Factor Number Mean mental
development score
(pre-HSCT vs.
1 year post-HSCT)
P value
for change
Age <8 months 9 92.3±13.0 0.0016
68.1±19.5
>8 months 7 92.9±13.4 0.0088
74.3±24.4
Serious
infections
Yes 13 91.1±13.5 0.0002
70.0±21.7
No 3 99.0±6.2 0.13
74.3±23.4
No. of
Transplants
1 13 92.8±13.7 0.0004
73.5±21.7
>1 3 91. 7±9.5 0.033
59.0±17.3
Length of stay <180 days 8 97.3±11.6 0.012
79.4±22.6
>180 days 8 87.9±12.8 0.0009
62.3±16.9
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Psychomotor Development (PDI)
There was no significant decrease in PDI during the first
year post-HSCT (82.4±18.8 vs. 84.8±23.0, p=0.69;
Fig. 2). Nine patients also received the Bayley at 3 years
post-HSCT. There was a significant decline in PDI scores
from pre- to 1 year to 3 years post-HSCT (86.3±17.4 vs.
86.0±19.7 vs. 74.1±15.6, p=0.05). The decline from pre-
HSCT to 1 year post-HSCT was not significant (p=0.96);
however, the subsequent decline from 1 year post to 3 years
post-HSCT was significant (p=0.008). There were no PDI
scores at 5 years post-HSCT.
Similar to the MDI scores, the median raw scores for PDI
also increased over time. Pre-HSCT PDI scores were 37 (7–
65) vs. 1-year post-HSCT scores of 77 (32–97). The nine
patients who received the Bayley at 3 years post-HSCT had a
median raw PDI score of 96 (72–103; Fig. 4b). The remaining
patients received the WPPSI at 3 years post-HSCT.
Adaptive Behavior (VABS)
The VABS scores also decreased significantly during the
first year post-HSCT (99.7±7.0 vs. 81.9±10.1, p=<0.0001,
n=11). Raw scores for the VABS were also analyzed. Mean
raw scores increased from 48 (12–82) pre-HSCT to 110
(77–149). Unlike the MDI and the PDI, there was a
significant correlation between age at the time of transplant
and change in adaptive living scores from pre- to 1 year
post-HSCT. Children who were<8 months of age had a
decrease in their VABS scores from 103.0±3.7 to 77.2±4.2,
whereas those who were >8 months had a significantly
smaller decrease from 97.0±8.2 to 85.8±12.3 (p=0.023).
Based on Spearman correlation coefficients, changes in the
VABS scores were independent of changes in the MDI (rs=
17, p=0.61) and the PDI (rs=0.24, p=0.47).
Discussion
SCID is a life-threatening genetic disease that may be cured
by the use of HSCT from a related or unrelated donor. Most
children are diagnosed after presenting with an opportunis-
tic infection. Many of these children have failure to thrive
and chronic diarrhea. Others have muscle wasting from
decreased nutrition. There have been several studies
looking at the neurodevelopmental function of children
undergoing HSCT. The largest of these studies examined
the neurodevelopmental function of 268 patients who
underwent HSCT. Although the majority of these patients
had a malignant diagnosis, most had minimal risk of long-
term neurodevelopmental delays. There were subgroups of
patients that were at risk, including those who received total
body irradiation (TBI), those receiving unrelated trans-
plants, and those with graft vs. host disease [16].
Our study shows that SCID patients have decreased
mental development 1 year post-HSCT, followed by a
stabilization in test scores over time. However, when
analyzing the raw scores of these patients, there was a
slow steady improvement over time. These raw scores
showed that patients with SCID acquired new developmen-
tal skills, but at a slower rate than their age-matched peers.
There are many possible explanations as to why patients
with SCID had a mental development that was slower than
their age-matched peers. First, there have been many
studies stating that chemotherapy/HSCT causes neurodeve-
lopmental deficits in young children [9–11]. These studies
were based mostly on patients who received chemotherapy
for leukemia. Leukemia patients receive much more
intensive therapy to their craniospinal axis (intrathecal
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Fig. 4 a Raw scores of mental development pre-, 1 year, and 3 years
post-HSCT. b Raw scores of psychomotor development pre-, 1 year,
and 3 years post-HSCT
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chemotherapy and possibly cranial irradiation), whereas
SCID patients do not receive the same intensity of
chemotherapy. We do not know the impact of chemother-
apy on the neurodevelopmental function of patients with
SCID since all of our patients received a myeloablative
transplant. Second, most patients with SCID are diagnosed
early in life after a severe infection. Many have been
hospitalized for an extensive period of time. Even after they
leave the hospital, they remain immunosuppressed and are
therefore socially isolated from other children for a
prolonged period. Many patients have no other siblings
and are not able to see and interact with any children. These
factors lead to a lack of exposure to developmental stimuli.
These factors seem a likely cause as to why there are
significant decreases in development for the first 3 years
post-HSCT. It is encouraging to see that those patients,
whose immunosuppression has decreased over time, are
able to lead more normal lifestyles. There were four
patients who were tested 5 years post-HSCT. These patients
have returned to school and have minimal immunosuppres-
sion. These four patients have overall development scores
that are comparable to their test scores prior to HSCT.
Our study does not appear to show an impact on motor
development the first year post-HSCT, but there is a
decrease in the overall motor development at 3 years post-
HSCT. A possible explanation for this is that while in the
hospital, patients receive physical therapy regularly. While
home, intensive physical therapy may not occur regularly.
Since these patients remain immunosuppressed, they are
not able to join playgroups and gym classes as other normal
toddlers do. Therefore, the psychomotor development
scores may decline until they have the ability to increase
social interactions.
Adaptive behavior scores show that the younger children
have worse adaptive function than those who were trans-
planted >8 months of age. Some of our patients were
diagnosed shortly after birth, since there had been a
previously affected child in the family. Unlike many of
the children who were diagnosed and transplanted later in
life, these children were hospitalized at birth and remained
in protective isolation until they were discharged home.
Being in the hospital at such an early age and not being
able to interact with outside stimulation is the most likely
cause of decreased adaptive function in our younger
children. We do not perform long-term adaptive behavioral
studied on these children, so we do not know if the adaptive
function improves once these children are discharged from
the hospital or not.
The majority of studies addressing the long-term neuro-
developmental function post-HSCT have focused on
patients with a variety of diseases (malignant and non-
malignant). The major limitation of this study as well as
other studies of neurocognitive outcomes post-pediatric
HSCT is the small sample size. SCID is a very rare disease,
so the numbers of patients in this study is small, which is
unavoidable. In addition, the presenting symptoms of
patients and their outcomes vary considerably. The strength
of this study is that all patients had the same diagnosis,
SCID. None of these patients had received prior chemo-
therapy, unlike patients have who received HSCT for a
malignant disease. The second strength of this study is that
all patients received a Busulfan-containing conditioning
regimen. There was not a mixture of both TBI and non-
TBI-based conditioning regimens as is seen in most
studies of this nature. We do not know the outcomes of
patients who did not receive a chemotherapy conditioning
regimen prior to HSCT. However, due to the social
isolation and prolonged immunosuppression that occurs
with any transplant for SCID, it is possible that the
neurocognitive function of all recipients of HSCT for
SCID will have some developmental delays until they are
able to increase their social interactions. Long-term
studies should focus on comparing those who did and
did not receive a chemotherapy conditioning regimen to
determine the impact on chemotherapy as well as social
isolation.
This study highlights the problems that clinicians and
parents will need to be aware of long term. It will be
important to try to integrate these children with normal
activities as soon as medically eligible. As these children
approach school, clinicians should be ready to work with
the school in implementing interventions as needed.
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